Zhitong Financial APP learned that on July 26th, the Shenzhen Municipal Development and Reform Commission formally issued a circular on three policy measures, including "Shenzhen's measures to promote the High-quality Development of Biopharmaceutical Industrial clusters", "Shenzhen's measures to promote the High-quality Development of High-end Medical device Industrial clusters" and "Shenzhen's measures to promote the High-quality Development of large and healthy Industrial clusters", to support related industries to become bigger and stronger. Guojin Securities believes that domestic leading companies with strong strength in innovative R & D and channel promotion are expected to conform to the development of the industry, and the new medical infrastructure in the post-epidemic era will accelerate the development of the domestic medical equipment market. Firmly optimistic about the medium-and long-term development prospects of leading enterprises in related industries. Related concept stocks: Shandong Weigao Group Medical Polymer (01066), Shanghai Fosun Pharmaceutical (02196), minimally invasive Medical treatment (00853), Qiming Medical-B (02500).
Among them, "some measures to promote the high-quality development of high-end medical device industry clusters in Shenzhen" shows that in order to increase the application and demonstration of innovative products, medical device enterprises are supported to be included in belt procurement. Enterprises are encouraged to actively participate in the national centralized procurement of medical devices to expand the market. The winning varieties will be subsidized according to 3% of the total purchase amount in that year, the maximum subsidy for a single variety shall not exceed 3 million yuan, and that of a single enterprise shall not exceed 5 million yuan per year.
In addition, the "measures" further pointed out that the ability of scientific and technological transformation and industrialization will be strengthened from five aspects. The first is to support the R & D and production of two and three types of medical devices. The second is to pay attention to the improvement of the characteristic service ability of medical device research and development and declaration. The third is to encourage the construction of medical device production sites. Fourth, encourage the local industrialization of medical device products. The fifth is to promote the participation of third-party organizations in clinical trial management. The sixth is to optimize the environment of medical device industry. Guojin Securities said that with the continuous release of new medical infrastructure policies for the diagnosis and treatment capacity building of grass-roots hospitals, superimposed national support for the development of the domestic medical equipment industry, the leading domestic equipment companies with strong innovative R & D and channel promotion capabilities in the future are expected to stand out.
According to the latest data from the Statistical Information Center of the Health Commission, by the end of 2021, there were 1.0309 million medical and health institutions in China. Compared with the same period last year, the number of medical and health institutions nationwide increased by 8013, of which the number of grass-roots medical and health institutions increased by 7754. There are 977800 primary medical and health institutions, including 36200 community health service centers (stations), 34900 township health centers, 271100 clinics and infirmaries, and 599300 village clinics. The construction of grass-roots medical institutions is expected to continue to deepen, and the demand for hospital equipment will continue for a long time.
From the perspective of market scale, benefiting from the development of economic level and the increasing demand for health, China's medical device market has ushered in a huge opportunity for development. According to the data of China Medical device Market Analysis report 2022-Industry Operation situation and Development trend Forecast, the scale of China's medical device market in 2019 is about 628.5 million yuan, an increase of 18.50% over the same period last year. It is estimated that the market size of China's medical device industry will reach 958.2 million yuan by 2022.
In terms of market concentration, according to statistics, the top 20 medical device markets in the world account for 54.5% of the total medical devices, and there are nearly 20, 000 domestic medical device manufacturing enterprises, but 90% of the companies' income is less than 20 million yuan. The market concentration of the top 20 listed companies is only 14.2%. There is a lot of room for improvement in the future.
Caixin Securities said that the new medical infrastructure is the trend of the times. Since 2020, due to the medical shortcomings exposed by the epidemic, the state has issued a series of policies and administrative orders to start hospital construction. The 14th five-year Plan emphasizes the construction of high-quality medical resources and regional balanced layout, improve the level of facilities and services in county-level hospitals, and further enhance the supply of high-quality medical service resources. In the post-epidemic era, the world strengthens public health construction, conforms to the wave of new medical infrastructure, and provides development opportunities for domestic medical device products to go out to sea. The process of domestic substitution and internationalization of medical device industry continues to accelerate. Caixin is optimistic about the R & D platform manufacturers of medical devices with independent innovation and the ability to go to sea.
Related concept stocks:
Shandong Weigao Group Medical Polymer (01066): the company mainly produces and sells disposable consumables, such as infusion devices, syringes and blood bags. Orthopaedic products Division produces and sells orthopedic products. Blood purification products Division produces and sells blood purification products and related medical equipment.
Shanghai Fosun Pharmaceutical (02196): the company is engaged in medical devices and medical diagnosis business as well as medical services, and its products are mainly sold to China's domestic and overseas markets.
Minimally invasive Medical (00853): the company is a leading medical device developer, manufacturer and marketer in China, focusing on minimally invasive interventional products for the treatment of vascular diseases and lesions.
Qiming Medical-B (02500): Qiming Medical-B (02500) is a Chinese company engaged in the development, manufacture and sale of minimally invasive medical equipment and auxiliary instruments and equipment for the treatment of valvular heart disease.